Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Previous studies have evidenced an association between gastroesophageal reflux and esophageal adenocarcinoma (EA). It is unknown to what extent these associations vary by population, age, sex, body mass index, and cigarette smoking, or whether duration and frequency of symptoms interact in predicting risk. The Barrett's and Esophageal Adenocarcinoma Consortium (BEACON) allowed an in-depth assessment of these issues.
Methods: Detailed information on heartburn and regurgitation symptoms and covariates were available from five BEACON case-control studies of EA and esophagogastric junction adenocarcinoma (EGJA). We conducted single-study multivariable logistic regressions followed by random-effects meta-analysis. Stratified analyses, meta-regressions, and sensitivity analyses were also conducted.
Results: Five studies provided 1,128 EA cases, 1,229 EGJA cases, and 4,057 controls for analysis. All summary estimates indicated positive, significant associations between heartburn/regurgitation symptoms and EA. Increasing heartburn duration was associated with increasing EA risk; odds ratios were 2.80, 3.85, and 6.24 for symptom durations of <10 years, 10 to <20 years, and ≥20 years. Associations with EGJA were slighter weaker, but still statistically significant for those with the highest exposure. Both frequency and duration of heartburn/regurgitation symptoms were independently associated with higher risk. We observed similar strengths of associations when stratified by age, sex, cigarette smoking, and body mass index.
Conclusions: This analysis indicates that the association between heartburn/regurgitation symptoms and EA is strong, increases with increased duration and/or frequency, and is consistent across major risk factors. Weaker associations for EGJA suggest that this cancer site has a dissimilar pathogenesis or represents a mixed population of patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116205 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0103508 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Single-cell analysis of Barrett's esophagus and carcinoma reveals cell types conferring risk via genetic predisposition.
Cell Genom
September 2025
Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. Electronic address:
Inherited genetic variants contribute to Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC), but it is unknown which cell types are involved in this process. We performed single-cell RNA sequencing of BE, EAC, and paired normal tissues and integrated genome-wide association data to determine cell-type-specific genetic risk and cellular processes that contribute to BE and EAC. The analysis reveals that EAC development is driven to a greater extent by local cellular processes than BE development and suggests that one cell type of BE origin (intestinal metaplasia cells) and cellular processes that control the differentiation of columnar cells are of particular relevance for EAC development.
View Article and Find Full Text PDFA Systematic Review of Risk Prediction Models for Esophageal Adenocarcinoma in the General Population.
Gastro Hep Adv
June 2025
Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China.
Background And Aims: Risk prediction models can identify individuals at high risk of esophageal adenocarcinoma. This systematic review aimed to critically appraise the available models for projecting absolute risk of esophageal adenocarcinoma in the general population.
Methods: We searched Medline, Embase, and Cochrane Library databases for studies of risk prediction models for esophageal adenocarcinoma.
Integrative GEO and Mendelian randomization analysis reveals transcriptomic and lipidomic features of esophageal adenocarcinoma.
Medicine (Baltimore)
August 2025
Department of Pathology, Affiliated Hospital 2 of Nantong University, Nantong, China.
Background: The incidence of esophageal adenocarcinoma (EA) has significantly increased in developed Western countries. Despite medical advancements, the prognosis remains poor, with a 5-year survival rate of less than 20%. By 2024, the global incidence is expected to reach 141,300 new cases annually, underscoring the urgent need to elucidate the mechanisms underlying EA pathogenesis to develop effective preventive and therapeutic strategies.
View Article and Find Full Text PDFNew Approaches to Screening for Barrett Esophagus.
Gastroenterol Hepatol (N Y)
June 2025
Division of Gastroenterology, Mayo Clinic, Jacksonville, Florida.
Current screening methods for Barrett esophagus (BE), the precursor to esophageal adenocarcinoma (EAC), are inadequate with less than one-third of screen-eligible patients currently undergoing screening. In addition to low screening rates, key issues include overemphasis on gastroesophageal reflux disease symptoms and lack of provider awareness, owing in part to heterogeneous guidelines. To address these challenges, several new approaches are being explored: swallowable cell collection devices, exhaled volatile organic compounds analysis, blood-based molecular biomarkers, microbiome analysis, and alternative visualization methods such as transnasal and capsule endos-copy.
View Article and Find Full Text PDFMulti-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA.
Front Oncol
August 2025
Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, United States.
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the early detection of esophageal cancer (EC), offering a minimally invasive means to assess tumor-derived genomic and epigenomic alterations. This review synthesizes current data on ctDNA biology, detection technologies, diagnostic performance, and clinical applicability in both esophageal adenocarcinoma and squamous cell carcinoma. We conducted a comprehensive literature review of PubMed-indexed studies on ctDNA in EC, emphasizing recent (January 1, 2019- December 31, 2024) findings, systematic reviews, and meta-analyses.
View Article and Find Full Text PDF